Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014, Article ID 939315, 9 pages
http://dx.doi.org/10.1155/2014/939315
Research Article

Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY)

1Ivey Eye Institute, St. Joseph’s Health Centre, 268 Grosvenor Street, London, ON, Canada N6A 4V2
2OptumInsight, 5500 North Service Road, Suite 501, Burlington, ON, Canada L7L 6W6
3Novartis Pharmaceuticals Canada, 385 Bouchard Boulevard, Dorval, QC, Canada H9S 1A9

Received 4 October 2013; Accepted 20 February 2014; Published 26 March 2014

Academic Editor: Tamer A. Macky

Copyright © 2014 John R. Gonder et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Moss, R. Klein, and B. E. Klein, “Ten-year incidence of visual loss in a diabetic population,” Ophthalmology, vol. 101, no. 6, pp. 1061–1070, 1994. View at Google Scholar · View at Scopus
  2. T. A. Ciulla, A. G. Amador, and B. Zinman, “Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies,” Diabetes Care, vol. 26, no. 9, pp. 2653–2664, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. W. Johnson, “Etiology and treatment of macular edema,” American Journal of Ophthalmology, vol. 147, no. 1, pp. 11.e1–21.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Petrella, J. Blouin, B. Davies, and M. Barbeau, “Prevalence, demographics, and treatment characteristics of visual impairment due to diabetic macular edema in a representative Canadian cohort,” Journal of Ophthalmology, vol. 2012, Article ID 159167, 6 pages, 2012. View at Publisher · View at Google Scholar
  5. The cost of vision loss in Canada: summary report, 2009, http://www.cnib.ca/eng/cnib%20document%20library/research/summaryreport_covl.pdf.
  6. K. Mazhar, R. Varma, F. Choudhury, R. McKean-Cowdin, C. J. Shtir, and S. P. Azen, “Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study,” Ophthalmology, vol. 118, no. 4, pp. 649–655, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. Canadian Diabetes Association, “An economic tsunami: the cost of diabetes in Canada,” 2009, http://www.diabetes.ca/documents/get-involved/FINAL_Economic_Report.pdf.
  8. American Academy of Ophthamology Retina Panel, Preferred Practice Pattern Guidelines. Diabetic Retinopathy, American Academy of Ophthamology, San Franciso, Calif, USA, 2008.
  9. J. A. O'Brien, A. R. Patrick, and J. Caro, “Cost of managing complications resulting from type 2 diabetes mellitus in Canada,” BMC Health Services Research, vol. 3, article 1, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. Shea, L. H. Curtis, B. G. Hammill et al., “Resource use and costs associated with diabetic macular edema in elderly persons,” Archives of Ophthalmology, vol. 126, no. 12, pp. 1748–1754, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. Statistics Canada, Consumer price index, http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ161a-eng.htm.
  12. Ontario Ministry of Health and Long-Term Care, “Ontario health insurance (OHIP) schedule of benefits and fees. Physician services,” http://www.health.gov.on.ca/english/providers/program/ohip/sob/sob_mn.html.
  13. Ontario Case Costing Initiative (OCCI), “OCCI Costing analysis tool. Fiscal year,” 2009, http://www.occp.com/mainPage.htm.
  14. A. Cruess, G. Zlateva, X. Xu, and S. Rochon, “Burden of illness of neovascular age-related macular degeneration in Canada,” Canadian Journal of Ophthalmology, vol. 42, no. 6, pp. 836–843, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. Statistics Canada, “Average hourly wages,” 2011, http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr69a-eng.htm.
  16. Ontario Ministry of Long-Term Care, “Drugs funded by Ontario drug benefit program,” http://www.health.gov.on.ca/english/providers/program/drugs/odbf_eformulary.html.
  17. C. M. Mangione, P. P. Lee, P. R. Gutierrez, K. Spritzer, S. Berry, and R. D. Hays, “Development of the 25-item National Eye Institute Visual Function Questionnaire,” Archives of Ophthalmology, vol. 119, no. 7, pp. 1050–1058, 2001. View at Google Scholar · View at Scopus
  18. K. Cheung, M. Oemat, M. Oppe M et al., “User guide: basic information on how to use EQ-5D,” 2009, http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/User_Guide_v2_March_2009.pdf.
  19. S. M. Hariprasad, W. F. Mieler, M. Grassi, J. L. Green, R. D. Jager, and L. Miller, “Vision-related quality of life in patients with diabetic macular oedema,” British Journal of Ophthalmology, vol. 92, no. 1, pp. 89–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. J. Browning, M. D. McOwen, R. M. Bowen Jr., and T. L. O'Marah, “Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography,” Ophthalmology, vol. 111, no. 4, pp. 712–715, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. “Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group,” Archives of Ophthalmology, vol. 103, no. 12, pp. 1796–1806, 1985. View at Publisher · View at Google Scholar
  22. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. L. J. Lee, A. P. Yu, K. E. Cahill et al., “Direct and indirect costs among employees with diabetic retinopathy in the United States,” Current Medical Research and Opinion, vol. 24, no. 5, pp. 1549–1559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. I. J. Suñer, G. T. Kokame, E. Yu, J. Ward, C. Dolan, and N. M. Bressler, “Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials,” Investigative Ophthalmology & Visual Science, vol. 50, no. 8, pp. 3629–3635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Soubrane, A. Cruess, A. Lotery et al., “Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study,” Archives of Ophthalmology, vol. 125, no. 9, pp. 1249–1254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Lloyd, B. Nafees, S. Gavriel, M. D. Rousculp, K. S. Boye, and A. Ahmad, “Health utility values associated with diabetic retinopathy,” Diabetic Medicine, vol. 25, no. 5, pp. 618–624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. E. K. Fenwick, J. Xie, J. Ratcliffe et al., “The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes,” Investigative Ophthalmology & Visual Science, vol. 53, no. 2, pp. 677–684, 2012. View at Google Scholar · View at Scopus
  28. S. Sharma, H. Hollands, G. C. Brown, M. M. Brown, G. K. Shah, and S. M. Sharma, “The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy,” Current Opinion in Ophthalmology, vol. 12, no. 3, pp. 230–234, 2001. View at Publisher · View at Google Scholar · View at Scopus